Angela Hwang stands as a luminary in the expansive realm of global biopharmaceuticals, charting the course for Pfizer's Biopharma business with unwavering commitment and foresight. Serving as the Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer, Angela leads a formidable organization comprising over 26,000 colleagues, working relentlessly to ensure the delivery of Pfizer's medicines and vaccines to patients in 185 countries. In 2022, Angela's impact resonated globally, with more than 1.3 billion people receiving Pfizer therapy, a resounding testament to her dedication to safeguarding and enhancing global health. Under her astute leadership, Pfizer Biopharma achieved an impressive financial milestone, generating a staggering $100 billion in revenues in the same year. Angela's influence extends beyond the boardroom of pharmaceutical giants. Pfizer's Biopharma business, under her strategic guidance, addresses major global health priorities, from cancer and COVID-19 to infectious diseases, inflammation & immunology, rare diseases, cardiovascular/metabolic disorders, and preventative care through vaccines. Yet, Angela's vision goes beyond the mere availability of medicines; she actively fosters collaborations with health insurers, governments, policymakers, and global health stakeholders worldwide. Her objective is not only to provide access to medicines but also to explore innovative solutions, ensuring healthcare is accessible and affordable for all. In 2020, Angela and her dedicated team achieved an extraordinary milestone by launching the world's first COVID-19 vaccine. Just a year later, they introduced the first oral antiviral treatment, defying conventional timelines for vaccine development. Angela's relentless focus on patient well-being transformed what seemed impossible into a reality. The roots of Angela's commitment to health equity delve into her upbringing as an Asian girl in South Africa during the apartheid era. This background informs her dedication to breaking barriers in healthcare accessibility. After an impressive 27-year tenure at Pfizer, Angela spearheaded the launch of "An Accord for a Healthier World." This groundbreaking initiative aims to ensure sustained, equitable access to all Pfizer medicines and vaccines in 45 lower-income countries, potentially improving the health of 1.2 billion people and transforming healthcare ecosystems. Angela's remarkable leadership hasn't gone unnoticed. She consistently earns recognition as one of the world's top leaders in healthcare and business by prestigious publications like Crain's, Business Insider, Forbes, and Fortune. Fortune placed her among the top 20 Most Powerful Women in Business for three consecutive years. Angela is also an A100 honoree, acknowledging her impactful contributions as an Asian American and Pacific Islander (AAPI) leader. In 2021, Angela received the President's Award from the National Diversity Council for championing diversity, equity, and inclusion. Cornell University honored her as a Robert S. Hatfield Economic Fellow in 2022, further underlining her distinguished achievements. Angela was recognized as an Ascend A-list Honoree the following year, solidifying her status as an exemplary Asian American leader.

click here